FDA approval summary: Pembrolizumab for treatment of metastatic non-small cell lung cancer: First-line therapy and beyond

Oncologist

Volumn 22, Issue 11, 2017, Pages 1392-1399

  Pai Scherf, Lee ^a   Blumenthal, Gideon M ^a   Li, Hongshan ^a   Subramaniam, Sriram ^a   Mishra Kalyani, Pallavi S ^a   He, Kun ^a   Zhao, Hong ^a   Yu, Jingyu ^a   Paciga, Mark ^a   Goldberg, Kirsten B ^a   McKee, Amy E ^a   Keegan, Patricia ^a   Pazdur, Richard ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

EGFR protein; Human; Non small cell lung cancer; Pembrolizumab; United States Food and Drug Administration

Indexed keywords

CARBOPLATIN; DOCETAXEL; GEMCITABINE; PACLITAXEL; PEMBROLIZUMAB; PEMETREXED; CD274 PROTEIN, HUMAN; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; MONOCLONAL ANTIBODY; PROGRAMMED DEATH 1 LIGAND 1; TAXOID;

ANEMIA; ARTICLE; COLITIS; DECREASED APPETITE; DISEASE COURSE; DISEASE SEVERITY; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSGEUSIA; FATIGUE; FOOD AND DRUG ADMINISTRATION; HISTOLOGY; HOSPITALIZATION; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; IMMUNOHISTOCHEMISTRY; INCIDENCE; INFUSION RELATED REACTION; MYOSITIS; NAUSEA; NEUTROPENIA; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SKIN MANIFESTATION; THROMBOCYTOPENIA; THYROIDITIS; VOMITING; ADULT; AGED; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; MIDDLE AGED; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; UNITED STATES; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; B7-H1 ANTIGEN; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE PROGRESSION; DRUG APPROVAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; RECEPTOR, EPIDERMAL GROWTH FACTOR; TAXOIDS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 85034085951     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2017-0078     Document Type: Article

References (13)

1. D’Addario G, Pintilie M, Leighl NB et al. Platinum-based versus non-platinum based chemotherapy in advanced non-small-cell lung cancer: A metaanalysis of the published literature. J Clin Oncol 2005;23:2926–2936.
2. Taxotere Prescribing Information. Available at http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020449s075lbl.pdf. Accessed July 19, 2017.
3. Erlotinib Prescribing Information. Available at http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021743s027lbl.pdf. Accessed July 19, 2017.
4. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Non-small cell lung cancer. Available at https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf. Accessed December 12, 2016.
5. National Cancer Institute: Lung Cancer. Available at https://www.cancer.gov/types/lung/hp/non-smallcell-lung-treatment-pdq. Accessed December 12, 2016.
6. Schiller JH, Harrington D, Belani CP et al. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med 2002;346:92–98.
7. Scagliotti GV, DeMarinis F, Rinaldi M et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small cell lung cancer. J Clin Oncol 2002;20:4285–4291.
8. Sul J, Blumenthal GM, Jiang X et al. FDA approval summary: Pembrolizumab for the treatment of patients with metastatic non-small cell lung cancer whose tumors express programmed deathligand 1. The Oncologist 2016;21:643–650.
9. Reck M, Rodríguez-Abreu D, Robinson AG et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 2016;375:1823–1833.
10. Herbst RS, Baas P, Kim DW et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial. Lancet 2016;387:1540–1550.
11. Keytruda Prescribing Information. Available at http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125514s012lbl.pdf. Accessed July 19, 2017.
12. Clinicaltrials.gov, Trial NCT02142738. Available at https://clinicaltrials.gov/ct2/show/NCT02142738. Accessed July 19, 2017.
13. Clinicaltrials.gov, Trial NCT02220894. Available at https://clinicaltrials.gov/ct2/show/NCT02220894. Accessed July 19, 2017.